논문업데이트
Home. 최근뉴스. 논문업데이트
Persistent nasal symptoms and mediator release after continuous pollen…
페이지 정보
본문
Ann Allergy Asthma Immunol. 2016 Jun 1. pii: S1081-1206(16)30265-4. doi: 10.1016/j.anai.2016.05.015. [Epub ahead of print]
Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber.
Okuma Y1, Okamoto Y2, Yonekura S1, Iinuma T1, Sakurai T3, Hamasaki S1, Ohki Y1, Yamamoto H4, Sakurai D1
Abstract
BACKGROUND:
Immediate- and late-phase reactions are associated with nasal symptoms of patients with allergic rhinitis.
OBJECTIVE:
To examine the symptoms and mediators released after continuous allergen exposure in an environmental challenge chamber (ECC).
METHODS:
Fifteen patients with Japanese cedar pollinosis were enrolled in this study and continuously exposed to cedar pollen at a concentration of 8,000 grains/m3 for 3 hours in an ECC. Nasal function tests were performed, and nasal secretions were collected before pollen exposure (0 hour), immediately after exiting the ECC (3 hours), and 6 hours after exiting the ECC (9 hours). Symptom scores were recorded every 30 minutes in the ECC and every 3 hours after exiting the ECC. The frequency of sneezing and nose blowing also was monitored.
RESULTS:
The severity of symptoms in the ECC peaked approximately 2 hours after the beginning of pollen exposure and continued more than 6 hours after leaving the ECC. Concentrations of histamine, tryptase, interleukins 5, 3, 33, and 31, and substance P increased over time, whereas that of nasal fractional exhaled nitric oxide decreased.
CONCLUSION:
Various mediators are released during continuous allergen exposure, which subsequently induce persistent nasal symptoms. Effective treatment is required to control the intense inflammation observed after allergen exposure.
-
- 이전글
- Molecular cloning of plane pollen allergen Pla a 3 and its utility as diagnostic marker for peach associated plane pollen allergy.
- 16.08.03
-
- 다음글
- Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
- 16.07.20
댓글목록
등록된 댓글이 없습니다.
